Medicare AdvantageAdministrativeMedium impact
MA08.082n, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.082n updates medical necessity criteria and medical coding requirements for G-CSF agents including Ryzneuta®, Rolvedon™, Neulasta®, and related biosimilars effective June 16, 2025. The billing team must review updated coverage criteria and ensure coding compliance for these hematopoietic agents used in oncology and chemotherapy support.
Action Required
By June 16, 2025: Billing team must access and review the full policy text at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=06&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma08-082n-efbemalenograstim-alfa-vuxw-ryz to identify specific medical necessity criteria and coding changes. Update billing system rules, prior authorization workflows, and provider documentation templates to reflect new requirements. Communicate changes to oncology and hematology providers. Ensure claims submissions include required medical necessity documentation for G-CSF agents. Failure to comply may result in claim denials or recoupment.